The Carlyle Group Inc.

▲ Bull Case

• ◆AlpInvest undervalued within sum-of-parts: $274M FY 2025 segment FRE at STEP-equivalent 20–25x multiples implies $5.5–6.9B standalone value (30–37% of CG market cap); should force re-rating once segment FRE crosses ~$330M.
• ◆Schwartz transformation execution pristine across 8 reporting quarters with every FRE/inflows/margin target met or beaten; if next 12–18 months deliver US buyout fund VI launch + Fortitude Re FRE doubling + first dividend increase, multiple re-rates from 14.9x to 20–22x, delivering $80–102/share (+56% to +98%).
• ◆Perpetual capital momentum is structural flywheel: Carlyle growing perpetual capital +15.7% CAGR with perpetual % expanding 33%→44% by FY 2030. Each 1pp expansion historically translates to ~0.3–0.5x FRE multiple expansion based on peer cross-section, structurally narrowing historical 67% discount to BX.

▼ Bear Case

• ◆Key-man event remains binary risk: Lee departure (August 2022) caused ~30% drawdown; Schwartz is 2.5 years into 6-year plan. Healthcare event, board conflict, or competing opportunity could re-run precedent. Bear case: ~$41/share (-20%).
• ◆Q1 2026 revenue miss could mark inflection from beat-streak to miss-cycle; if Q2 2026 also misses, multiple compresses to 12x, FRE growth halts at 5–7%, stock trades $41–45 for 18 months as Schwartz credibility re-anchors.
• ◆Structural multiple discount persistence: Even with successful execution, BX's 50% perpetual, 58% FRE margin, retail distribution moat commands 30–40% premium that may never close. If CG re-rates to only 16–17x, upside is $58–62 rather than $63–66.

“Is the 40–45% FRE multiple discount to KKR/BX structural or closing? Closing camp: FRE margin improved 37%→47% in 3 years; AlpInvest +60% FRE growth proves franchise positioning; perpetual capital build on track; catalysts include US buyout fund VI, Fortitude Re FRE doubling; price targets $60–75. Structural camp: BX scale (2.5x AUM), 50% perpetual base, BREIT retail moat, brand premium keep discount above 30%; CG compounds 10–12%/yr but multiple stays 13–15x; price targets $50–55. Our view: discount is closing but not eliminating—base case 18x P/FRE (still 30–35% discount to peers) is right anchor.”

• ◆US Buyout Fund VI launch / first close (6–18 months): +5–10% stock; +$100–150M FRE run-rate
• ◆AlpInvest pending FEAUM activation ($17B) (6–12 months): +$50–80M FRE; +3–5% stock uplift
• ◆First dividend increase from $1.40 (first in 4 years) (6–18 months): +5–8% multiple re-rating
• ◆Fortitude Re AUM expansion / FRE doubling (12–24 months): +$50–100M FRE contribution
• ◆Q2/Q3 2026 FRE margin recovery to 47%+ (3–6 months): Validates margin trajectory post Q1 miss

• ◆Key-man event (Schwartz or founder departure): 25–35% probability; -20–30% stock (Lee 2022 precedent)
• ◆Fundraising cycle slowdown (inflows < $35B): 30–40% probability; -5–10% FRE growth impact
• ◆Q1 2026 miss extends to Q2/Q3: 30% probability; multiple compression to 12x; -15–20% stock
• ◆Structural multiple discount persists despite execution: 40–50% probability; base case becomes bear
• ◆Carried interest tax reform at ordinary income rates: 15–25% probability; -2–5% margin via comp pressure